Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments

Teresa Battaglia; Elisa De Grandis; Marisol Mirabelli-Badenier; Luca Boeri; Guido Morcaldi; Paola Barabino; Chiara Intra; Francesca Naselli; Vito Pistoia; Edvige Veneselli; Massimo Conte

doi:10.1016/j.ejpn.2011.05.013

Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments

Teresa Battaglia, Elisa De Grandis, Marisol Mirabelli-Badenier, Luca Boeri, Guido Morcaldi, Paola Barabino, Chiara Intra, Francesca Naselli, Vito Pistoia, Edvige Veneselli, Massimo Conte

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.

Original language	English
Pages (from-to)	192-195
Number of pages	4
Journal	European Journal of Paediatric Neurology
Volume	16
Issue number	2
DOIs	https://doi.org/10.1016/j.ejpn.2011.05.013
Publication status	Published - Mar 2012

Keywords

Opsoclonus-myoclonus syndrome
Paraneoplastic syndromes
Rituximab
Treatment

ASJC Scopus subject areas

Clinical Neurology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.ejpn.2011.05.013

Fingerprint Dive into the research topics of 'Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments'. Together they form a unique fingerprint.

Cite this

Battaglia, T., De Grandis, E., Mirabelli-Badenier, M., Boeri, L., Morcaldi, G., Barabino, P., Intra, C., Naselli, F., Pistoia, V., Veneselli, E., & Conte, M. (2012). Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. European Journal of Paediatric Neurology, 16(2), 192-195. https://doi.org/10.1016/j.ejpn.2011.05.013

Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. / Battaglia, Teresa; De Grandis, Elisa; Mirabelli-Badenier, Marisol; Boeri, Luca; Morcaldi, Guido; Barabino, Paola; Intra, Chiara; Naselli, Francesca; Pistoia, Vito; Veneselli, Edvige; Conte, Massimo.

In: European Journal of Paediatric Neurology, Vol. 16, No. 2, 03.2012, p. 192-195.

Research output: Contribution to journal › Article › peer-review

Battaglia, T, De Grandis, E, Mirabelli-Badenier, M, Boeri, L, Morcaldi, G, Barabino, P, Intra, C, Naselli, F, Pistoia, V, Veneselli, E & Conte, M 2012, 'Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments', European Journal of Paediatric Neurology, vol. 16, no. 2, pp. 192-195. https://doi.org/10.1016/j.ejpn.2011.05.013

Battaglia, Teresa ; De Grandis, Elisa ; Mirabelli-Badenier, Marisol ; Boeri, Luca ; Morcaldi, Guido ; Barabino, Paola ; Intra, Chiara ; Naselli, Francesca ; Pistoia, Vito ; Veneselli, Edvige ; Conte, Massimo. / Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. In: European Journal of Paediatric Neurology. 2012 ; Vol. 16, No. 2. pp. 192-195.

@article{9df5020e014042399dcabfacbc52c251,

title = "Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments",

abstract = "We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.",

keywords = "Opsoclonus-myoclonus syndrome, Paraneoplastic syndromes, Rituximab, Treatment",

author = "Teresa Battaglia and {De Grandis}, Elisa and Marisol Mirabelli-Badenier and Luca Boeri and Guido Morcaldi and Paola Barabino and Chiara Intra and Francesca Naselli and Vito Pistoia and Edvige Veneselli and Massimo Conte",

year = "2012",

month = mar,

doi = "10.1016/j.ejpn.2011.05.013",

language = "English",

volume = "16",

pages = "192--195",

journal = "European Journal of Paediatric Neurology",

issn = "1090-3798",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments

AU - Battaglia, Teresa

AU - De Grandis, Elisa

AU - Mirabelli-Badenier, Marisol

AU - Boeri, Luca

AU - Morcaldi, Guido

AU - Barabino, Paola

AU - Intra, Chiara

AU - Naselli, Francesca

AU - Pistoia, Vito

AU - Veneselli, Edvige

AU - Conte, Massimo

PY - 2012/3

Y1 - 2012/3

N2 - We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.

AB - We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.

KW - Opsoclonus-myoclonus syndrome

KW - Paraneoplastic syndromes

KW - Rituximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84857367145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857367145&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2011.05.013

DO - 10.1016/j.ejpn.2011.05.013

M3 - Article

C2 - 21737325

AN - SCOPUS:84857367145

VL - 16

SP - 192

EP - 195

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 2

ER -

Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this